A study on tailored treatment for advanced urinary tract cancer after surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a system that helps doctors choose the best additional treatment for people with advanced upper tract urothelial cancer (UTUC) after their surgery. It focuses on patients whose cancer has spread into the muscle layer or beyond, or to nearby lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with upper tract urothelial cancer (cancer in the lining of the kidney or ureter).
- Your cancer has grown into or past the muscle layer (stage pT2 or higher), or has spread to nearby lymph nodes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.